|drug2814||Resting 12 lead ECG Wiki||1.00|
|drug848||Contrast-enhanced CMR Wiki||1.00|
|drug38||24 hour Holter ECG Wiki||1.00|
There is one clinical trial.
The aim of this study is to assess the prevalence and arrhythmogenic role of occult myocardial scars on Cardiac Magnetic Resonance (CMR) in a population of patients with history of laboratory-proven symptomatic COVID-19 infection managed without hospitalization, as compared to a population of age- and sex-matched healthy volunteers.
Description: Expressed in percentage of participant, as assessed on late gadolinium-enhanced magnetic resonance acquired at high resolution using a free breathing 3D method.Measure: Prevalence of myocardial scars Time: Day 0
Description: Measured in mLMeasure: CMR feature : Location and size of myocardial scars Time: Day 0
Description: Measured in millisecondsMeasure: CMR feature : native T1 and T2 values Time: Day 0
Description: Measured in percentageMeasure: CMR feature : extracellular volume fraction Time: Day 0
Description: Measured in mL/m2Measure: CMR feature : ventricular volumes Time: Day 0
Description: Measured in percentageMeasure: CMR feature : ejection fraction Time: Day 0
Description: Measured in percentageMeasure: CMR feature : myocardial strain Time: Day 0
Description: Repolarization abnormalities, T wave inversion, ST segment abnormalities, QRS fractionation, atrial arrhythmias, premature ventricular beats or ventricular tachycardia.These will be assessed at the time of CMR study on a resting 12-lead ECG recording and on exercise 12-lead ECG and 24-hour Holter ECG recordings.Measure: ECG features Time: Baseline and month 3
Description: Rate of seropositivity in asymptomatic volunteers and rate of seronegativity in patients with a history of symptomatic episodes. Measured in percentage.Measure: Biological feature : positivity of COVID-19 serology Time: Baseline and month 3
Description: Measured in fg/mlMeasure: Biological feature : troponin level Time: Day 0
Description: Markers of inflammation and fibrosis will be sought. The Th1/Th2/activation/inflammation/apoptosis markers will be measured in the sera by a Luminex test allowing the detection of 48 analytes.Measure: Biological feature : inflammatory markers level Time: Day 0
Description: Identified by sequencing genetic variants that could have an impact on the occurrence of a severe form in individuals infected with COVID-19Measure: Genetic profile research Time: Day 0
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports